2 weeks Ago By Defense World Staff
Sei Investments Co. increased its holdings in Royalty Pharma plc ( NASDAQ:RPRX – Free Report ) by 58.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC.
The institutional investor owned 109,557 shares of the biopharmaceutical company’s stock after acquiring an additional 40,271 shares during the quarter. Sei Investments Co.’s holdings in Royalty Pharma were worth $2,795,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Brooklyn Investment Group boosted its stake in shares of Royalty Pharma by 1,006.9% during the 4th quarter.
Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 876 shares during the last quarter. Allworth Financial LP raised its holdings in Royalty Pharma by 417.6% in the fourth quarter.
Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 877 shares in the last quarter. Riverview Trust Co grew its holdings in Royalty Pharma by 3,953.3% during the 4th quarter.
Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,186 shares in the last quarter. Fifth Third Bancorp increased its position in shares of Royalty Pharma by 187.1% in the 4th quarter.
Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 997 shares during the last quarter. Finally, Rakuten Securities Inc. raised its stake in shares of Royalty Pharma by 160.
5% in the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 1,003 shares in the last quarter.
Hedge funds and other institutional investors own 54.35% of the company’s stock. Analysts Set New Price Targets A number of equities analysts recently commented on the company.
Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a research note on Friday, March 28th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock.
Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $41.60.
Royalty Pharma Stock Performance Shares of NASDAQ RPRX opened at $31.11 on Friday. The company has a quick ratio of 1.
44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.
The firm’s 50-day moving average price is $32.52 and its two-hundred day moving average price is $28.96.
Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.20.
The stock has a market capitalization of $17.93 billion, a P/E ratio of 21.46, a P/E/G ratio of 2.
31 and a beta of 0.50. Royalty Pharma ( NASDAQ:RPRX – Get Free Report ) last announced its quarterly earnings results on Tuesday, February 11th.
The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.
16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.
94%. As a group, sell-side analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current year.
Royalty Pharma Increases Dividend The company also recently declared a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were given a dividend of $0.22 per share.
The ex-dividend date was Friday, February 21st. This represents a $0.88 annualized dividend and a dividend yield of 2.
83%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21.
Royalty Pharma’s dividend payout ratio is currently 60.69%. About Royalty Pharma ( Free Report ) Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Featured Stories Five stocks we like better than Royalty Pharma Insider Trading – What You Need to Know Archer Aviation’s Africa Deal Could Boost ACHR Stock Stock Dividend Cuts Happen Are You Ready? Are Short Sellers Wrong About These 3 Semiconductor Stocks? 2 Rising CRM Platform Stocks That Can Surge Higher in 2025 Boeing Gets $50B in March Orders—Is BA Stock a Buy Now? Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Royalty Pharma plc ( NASDAQ:RPRX – Free Report ). Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter .
.
